Alyeska Investment Group
BTTX

Alyeska Investment Group’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Alyeska Investment Group’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,032
Closed -$23K – 532
2022
Q2 		$23K Sell
15,032
-221,899
-94% -$371K ﹤0.01% 559
2022
Q1 		$469K Sell
236,931
-107,239
-31% -$371K 0.01% 550
2021
Q4 		$1.6M Buy
344,170
+329,770
+2,290% +$2.7M 0.02% 474
2021
Q3 		$144K Hold
14,400
– – ﹤0.01% 663
2021
Q2 		$143K Buy
+14,400
New +$143K ﹤0.01% 690

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alyeska Investment Group's BTTX Position: Q3 2022 in Review

Alyeska Investment Group sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q3 2022, closing a stake of 15,032 shares — an estimated $23K sold.

Alyeska Investment Group first reported a position in BTTX in Q2 2021 and held it in 5 quarters. The position peaked at $1.6M in Q4 2021. 16 funds tracked by Wall St. Rank hold BTTX as of Q3 2022.

  • Alyeska Investment Group reported no remaining Better Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 15,032 Better Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $23K.
  • Alyeska Investment Group first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Alyeska Investment Group's Better Therapeutics, Inc. Common Stock position peaked at $1.6M in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.